Pharmacokinetics, Toxicities, and Efficacies of Sodium Stibogluconate Formulations after Intravenous Administration in Animals

Nieto, Javier; Alvar, Jorge; Mullen, Alexander B.; Carter, K. C.; Rodríguez, C.; Andrés, M. I. San; Andrés, M. D. San; Baillie, A. J.; González, F.

doi:10.1128/aac.47.9.2781-2787.2003

Cited by 38 publications

(27 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In humans [6,8], monkeys [9], dogs [10], mice [11], hamsters [12] and rats [13,14], the decreases in the Sb blood levels with time after Sb V drug injection fit a two-compartment (or even multicompartment) kinetic model. The slow elimination phase of the bi-exponential decline of the Sb blood levels has a half-life longer than 24 h. This fact explains the therapeutic and toxic effects resulting from the repeated administration of doses administered at 24-h intervals (generally a three-week course of treatment) [6,9,13].…”

Section: Introductionmentioning

confidence: 93%

Effects of in utero and lactational exposure to SbV on rat neurobehavioral development and fertility

Coelho

De-Carvalho

Rocha

et al. 2014

Reproductive Toxicology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 93%

Effects of in utero and lactational exposure to SbV on rat neurobehavioral development and fertility

Coelho

De-Carvalho

Rocha

et al. 2014

Reproductive Toxicology

View full text Add to dashboard Cite

“…Despite the increased leishmanicidal activity of antimonial drugs, no liposomal formulation of Sb has reached the market so far. Furthermore, some experimental formulations produced acute toxicity in dogs, including chills and diarrhea, which cleared by 24 h postdosing, and hepatic dysfunction at 24 h postdosing (Nieto et al 2003).…”

Section: Introductionmentioning

confidence: 99%

Complement activation-related pseudoallergy in dogs following intravenous administration of a liposomal formulation of meglumine antimoniate

et al. 2013

View full text Add to dashboard Cite

Pesq. Vet. Bras. 33(8):1016Bras. 33(8): -1020Bras. 33(8): , agosto 2013Bras. 33(8): 1016 RESUMO.-[Pseudoalergia relacionada à ativação do complemento em cães após administração intravenosa de uma formulação lipossomal de antimoniato de meglumina.] O crescente uso das nanotecnologias nas terapias avançadas tem permitido a observação de reações adversas específicas relacionadas às nanoestruturas. A toxicidade de uma nova formulação lipossomal de antimoniato de meglumina após dose única foi avaliada em cães com leishmaniose visceral. The increasing use of nanotechnologies in advanced therapies has allowed the observation of specific adverse reactions related to nanostructures. The toxicity of a novel liposome formulation of meglumine antimoniate in dogs with visceral leishmaniasis after single dose has been investigated. Groups of 12 animals received by the intravenous route a single dose of liposomal meglumine antimoniate (group I [GI], 6.5 mg Sb/kg), empty liposomes (GII) or isotonic saline (GIII). Evaluation of hematological and biochemical parameters showed no significant changes 4 days after administration. No undesired effects were registered in the GIII. However, adverse reactions were observed in 67.7% of dogs from both groups that received liposomal formulations. The side effects began moments after bolus administration and disappeared during the first 15 minutes after treatment. Prostation, sialorrhea and defecation were the most frequent clinical signs, registered in 33.3% and 41.6 % of animals from the groups GI and GII, respectively. Tachypnea, mydriasis, miosis, vomiting and cyanosis were also registered in both groups. The adverse reactions observed in this study were attributed to the activation of the complement system by lipid vesicles in a phenomenon known as Complement Activation-Related Pseudoallergy (CARPA). The influence of the physical-chemical characteristics of liposomal formulation in the triggering of CARPA is discussed.

show abstract

“…The plasma half-life of miltefosine was determined to be 96 h (25), and the volume of distribution was 0.7 liters/kg after oral administration in rats (19). Sodium stibogluconate had a longer half-life (1.46 h) and a smaller volume of distribution (0.25 liters/kg) when administered intravenously to dogs (29).…”

mentioning

confidence: 99%

In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs

Seifert

Croft

2006

Antimicrob Agents Chemother

184

119

View full text Add to dashboard Cite

Pharmacokinetics, Toxicities, and Efficacies of Sodium Stibogluconate Formulations after Intravenous Administration in Animals

Cited by 38 publications

References 33 publications

Effects of in utero and lactational exposure to SbV on rat neurobehavioral development and fertility

Effects of in utero and lactational exposure to SbV on rat neurobehavioral development and fertility

Complement activation-related pseudoallergy in dogs following intravenous administration of a liposomal formulation of meglumine antimoniate

In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs

Contact Info

Product

Resources

About